PerkinElmer (Massachusetts, USA) has announced the acquisition of Haoyuan Biotech (Shanghai, China), an infectious disease diagnostics company, for the reported amount of $38 million.
PerkinElmer (Massachusetts, USA) has announced the acquisition of Haoyuan Biotech (Shanghai, China), an infectious disease diagnostics company, for the reported amount of $38 million. The acquisition promises to advance the clinical diagnostics capabilities of PerkinElmer, establishing their foothold on the rapidly growing Chinese market.
Haoyan Biotech focuses on the delivery of molecular diagnostics used within blood bank and clinical settings in China. The acquisition will result in the addition of four diagnostic assays to PerkinElmer’s portfolio that are approved by China’s state Food and Drug Administration (SFDA).
"By combining PerkinElmer's robust disease-screening capabilities with Haoyuan's proprietary reagents and equipment, the company will be able to offer highly sensitive systems and assays for quality detection of blood-borne infections for the Chinese market," commented Robert Friel, chairman and chief executive officer of PerkinElmer. "Integrating Haoyuan's screening products with PerkinElmer's diagnostics capabilities will help to further advance the health of the Chinese people by offering leading technology that ensures accurate diagnosis of infectious diseases at a low cost."
For more information please visit:
ref=http://www.perkinelmer.co.uk>www.perkinelmer.co.uk
Presenting GC Data Comparisons to Laypersons to Understand Potential Courtroom Implications
January 6th 2025In forensic science, scientific testimony is routinely presented in court to juries who may have limited or no scientific background, putting law enforcement and defense personnel in the position of having to make rapid decisions in short timeframes based on findings of which they are not specialists. Katelynn Perrault Uptmor, Assistant Professor of Chemistry at William & Mary (Williamsburg, Virginia) believes that the introduction of new technologies into the framework of routine forensic analysis must therefore bridge the gap between introduction of new and novel analytical science and the communication of that science to a court of law, and that analytical chemistry research must be mindful of the need to fill this gap in promoting new technologies.
Detailed Glycosylation Analysis of Therapeutic Enzymes Utilizing Comprehensive 2D-LC–MS
January 3rd 2025In this article, the use of comprehensive two-dimensional liquid chromatography (LC×LC) coupled to mass spectrometry (MS) for characterizing glycosylation of therapeutic enzymes is presented.
Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.